Anti-Coronavirus Therapies to Prevent Progression of COVID-19 Trial
ACT-COVID-19 is a randomized clinical trial to assess therapies to reduce the clinical progression of Coronavirus disease 2019 (COVID-19).
The ACT-COVID-19 program consists of two parallel trials evaluating azithromycin and chloroquine therapy versus usual care in outpatients and inpatients who have tested positive for severe acute respiratory syndrome coronavirus 2 (COVID-19). The trial is an open-label, parallel group, randomized controlled trial with an adaptive design. Adaptive design features include adaptive intervention arms and adaptive sample size based on new and emerging data.
Open-label randomized controlled trial
Primary outcome: Hospital admission or death.
Secondary outcomes: Mortality; invasive mechanical ventilation; admission to intensive care unit; renal replacement therapy; extracorporeal support.
Primary outcome: Composite of invasive mechanical ventilation or mortality (and its components).
Secondary outcomes: Admission to intensive care unit; renal replacement therapy; extracorporeal support.
Richard Whitlock, Emilie Belley-Cote, Salim Yusuf, Mark Loeb, Dominik Mertz, Sonia Anand, John Eikelboom, Jackie Bosch, Darryl Leong, Hertzel Gerstein
Mark Loeb, Department of Pathology and Molecular Medicine, McMaster University
Dominik Mertz, Division of Infectious Diseases, Department of Medicine, McMaster University